On October 20, 2020 Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that it is filing a Current Report on Form 8-K with the Securities and Exchange Commission (SEC), in which it will furnish an updated corporate presentation (Press release, Replimune, OCT 20, 2020, View Source [SID1234568686]). The presentation can be found in the "Investors and Media" section of Replimune’s corporate website under the "Events and Presentations" section (Link to Presentation).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation includes information relating to the abstracts that are to be presented at the 2020 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, including updated clinical trial data from the related trials, and other updated information about Replimune. The data from these abstracts appeared briefly and in error on the SITC (Free SITC Whitepaper) website on October 14, 2020, prior to their intended release on November 9, 2020. As a result, the full abstracts were released by Replimune on that date, and are being followed up with data in Replimune’s updated corporate presentation today.